RNA-Based Viral Vectors

Total Page:16

File Type:pdf, Size:1020Kb

RNA-Based Viral Vectors Review RNA-based viral vectors Expert Rev. Vaccines Early online, 1–30 (2014) Mark A Mogler1 and The advent of reverse genetic approaches to manipulate the genomes of both positive (+) and Kurt I Kamrud*2 negative (-) sense RNA viruses allowed researchers to harness these genomes for basic research. Manipulation of positive sense RNA virus genomes occurred first largely because infectious RNA 1Harrisvaccines, Inc., 1102 Southern Hills Drive, Suite 101, Ames, IA 50010, could be transcribed directly from cDNA versions of the RNA genomes. Manipulation of USA negative strand RNA virus genomes rapidly followed as more sophisticated approaches to 2Synthetic Genomics Vaccines, Inc., provide RNA-dependent RNA polymerase complexes coupled with negative-strand RNA 11149 North Torrey Pines, La Jolla, CA templates were developed. These advances have driven an explosion of RNA virus vaccine vector 90237, USA *Author for correspondence: development. That is, development of approaches to exploit the basic replication and expression [email protected] strategies of RNA viruses to produce vaccine antigens that have been engineered into their genomes. This study has led to significant preclinical testing of many RNA virus vectors against a wide range of pathogens as well as cancer targets. Multiple RNA virus vectors have advanced through preclinical testing to human clinical evaluation. This review will focus on RNA virus vectors designed to express heterologous genes that are packaged into viral particles and have progressed to clinical testing. KEYWORDS: alphavirus • flavivirus • orthomyxovirus • paramyxovirus • reverse genetics • rhabdovirus • RNA virus vector This review will describe RNA virus vector nsP3 and nsP4) are translated from the genomic development and the reverse genetics approaches RNA. The nsP2 is a viral protease that processes used to support the development for five RNA the nonstructural polyprotein into its individual virus families: Togaviridae, Flaviviridae, Ortho- subunits that function to transcribe negative- For personal use only. myxoviridae, Rhabdoviridae and Paramyxoviri- sense as well as new positive-sense viral RNA. dae. The RNA vector system(s) designed for The negative-sense replicative intermediate each will be described and a summary of preclin- RNA codes for a subgenomic promoter (26S ical work that has supported advanced testing promoter) that is recognized by the nonstruc- and human clinical evaluation will also be dis- tural proteins and is used to generate a subge- cussed. Although some systems have developed nomic mRNA that represents the 3´ one-third DNA-based vectors, only RNA particle-based of the genome; the viral structural proteins are systems will be discussed in this review. Reverse translated from this subgenomic mRNA. Repli- genetics systems for the generation of viruses in cation occurs completely in the cytoplasm of the Arenaviridae family have been described, but cells and progeny viruses bud at the plasma these RNA vectors are still in very early develop- membrane as virus capsid protein encapsidates Expert Review of Vaccines Downloaded from informahealthcare.com by 174.97.229.189 on 11/08/14 ment and therefore will not be examined in this genomic RNA and associates with the envelope review. Finally, reverse genetics approaches to glycoproteins that accumulate on the membrane develop Lentivirus vectors are well established of infected cells [2,3]. but will not be covered here as they have recently Because alphaviruses are positive-sense RNA been reviewed elsewhere [1]. viruses, full-length cDNA clones of their genomes can be used to generate RNA transcripts Togaviridae that, when introduced into susceptible cells, will Genus: Alphavirus initiate a complete virus replication cycle and Alphaviruses have a single-strand, positive-sense generate infectious virus. Manipulation of alpha- RNA genome that carries a 5´ 7-mG cap and a virus genomes is possible through introduction of 3´ polyadenylated region. The alphavirus non- mutations/modifications to the cDNA of their structural proteins are coded for in the 5´ two- respective clones. Two types of alphavirus vectors thirds of the genome and the structural proteins have been developed to express heterologous are coded for in the 3´ one-third of the genome. genes: propagation-competent vectors where a The nonstructural proteins (termed nsP1, nsP2, 26S promoter region is duplicated, either informahealthcare.com 10.1586/14760584.2015.979798 Ó 2014 Informa UK Ltd ISSN 1476-0584 1 Review Mogler & Kamrud upstream or downstream of a complete structural gene region, that intravenously has been described and preliminary data have drives expression of a foreign gene or propagation-defective repli- been provided that indicate this formulation (1 Â 108 or con vectors where a foreign gene is inserted in place of the struc- 5 Â 109 particles/m2 body surface) was well tolerated and that tural protein gene region [4,5]. The replicon RNA can be packaged a transient increase (five- to tenfold) in IL-12 serum levels was into virus replicon particles (VRP) by supplying the structural pro- detected within the first 3–4 days after injection [16–18]. tein genes in trans. Replicon RNA is packaged into VRP when cells A complete summary of the clinical outcomes of this clinical are cotransfected with helper RNA which encode the full comple- trial has not yet been published. A study protocol for a ment of structural proteins. A split helper system that provides the Phase I/II clinical trial using continuous intratumoral infusion structural proteins on separate helper RNAs greatly reduces the of LSFV-IL12 in recurrent glioblastoma multiforme patients chance of an intact genome being regenerated by RNA–RNA has been described, but no data are available on the status of recombination. Thus, the VRP are defective, in that they can infect this clinical trial [18]. target cells in culture or in vivo and can express the foreign gene at high levels, but they lack critical portions of the genome (i.e., the Venezuelan equine encephalitis vectors structural protein genes) necessary to produce virus particles which Development of VEEV VRP for human clinical evaluation has could spread to other cells [4,5]. Chimeric alphavirus vectors have occurred in both an infectious disease and cancer setting [20–23]. also been developed where the structural region of one alphavirus VEEV VRP vaccines have been tested preclinically against a is exchanged for a different alphavirus structural region; the result- large range of pathogens (TABLE 1), of which only a few have pro- ing chimeric alphavirus is usually attenuated in nature [6–10]. gressed into human clinical evaluation. Some notable VEEV Alphavirus replicon vectors have been developed from a VRP preclinical testing examples include successful vaccines number of viruses within the Togaviridae family; these viruses developed against Ebola virus (EBOV), Marburg virus, Lassa consist of Salmonid alphavirus, Chikungunya virus (CHIKV), virus, Smallpox virus, equine encephalitis viruses, Clostridium Sindbis-like XJ-160, Venezuelan equine encephalitis virus botulinum neurotoxins and anthrax [24–30]; detailed descriptions (VEEV), Sindbis and Semliki forest virus (SFV), with the of these studies are not provided here in order to focus on majority of vaccine development having been conducted with those VEEV VRP vaccines that have progressed into human VEEV, Sindbis and SFV [4,11–15]. clinical evaluation. Alphavirus vectors have been developed against a large num- The initial human evaluation of a VEEV VRP vaccine was ber of pathogens. A representative list of the many alphavirus with a replicon expressing an HIV antigen carried out by vector particle-based vaccines developed and tested preclinically AlphaVax, Inc. The sequence of an HIV-1 Clade C gag gene is presented in TABLE 1. This review will focus on alphavirus vec- was identified based on a prevalent virus circulating in South For personal use only. tor particle vaccines that have reached human clinical testing or Africa, where one arm of the clinical trial would take have achieved regulatory approval/licensure to highlight how place [31,32]. This first-in-man testing of the VEEV-gag VRP far this vaccine platform has progressed. Clinical evaluation of (AVX101) vaccine demonstrated that the vaccine was safe and VRP vaccines has occurred for a number of infectious diseases well tolerated, but unlike the robust immune responses noted and cancer indications using the VEEV and SFV VRP systems. in preclinical testing of AVX101, anti-Gag immune responses in humans were limited [23]. The AVX101 vaccine expressed a Semliki forest virus vectors nonmyristoylated HIV gag gene and it is known that myristoy- To the best of our knowledge, SFV vectors have only been lation of the Gag protein is important in the production of examined clinically in a cancer setting and with the gene of Gag-derived virus-like particles (VLP) [33,34]. Furthermore, a interest being a cytokine (IL-12). Preclinical studies for the VEEV-gag VRP expressing a myristoylated version of the gag oncolytic nature of SFV supported its use in this setting [16–19]. gene was preliminarily reported to be more immunogenic in Expert Review of Vaccines Downloaded from informahealthcare.com by 174.97.229.189 on 11/08/14 A SFV replicon vector expressing murine IL-12 genes was nonhuman primates than the AVX101 VRP, suggesting that shown to have oncogenic activity when injected directly into the Gag myristoylation mutation (inhibiting
Recommended publications
  • Recognition TLR7 Signaling Beyond Endosomal Dendritic Cells
    Flavivirus Activation of Plasmacytoid Dendritic Cells Delineates Key Elements of TLR7 Signaling beyond Endosomal Recognition This information is current as of September 29, 2021. Jennifer P. Wang, Ping Liu, Eicke Latz, Douglas T. Golenbock, Robert W. Finberg and Daniel H. Libraty J Immunol 2006; 177:7114-7121; ; doi: 10.4049/jimmunol.177.10.7114 http://www.jimmunol.org/content/177/10/7114 Downloaded from References This article cites 38 articles, 21 of which you can access for free at: http://www.jimmunol.org/content/177/10/7114.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 29, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2006 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Flavivirus Activation of Plasmacytoid Dendritic Cells Delineates Key Elements of TLR7 Signaling beyond Endosomal Recognition1 Jennifer P. Wang,2* Ping Liu,† Eicke Latz,* Douglas T. Golenbock,* Robert W. Finberg,* and Daniel H.
    [Show full text]
  • Innate Immunity Evasion by Dengue Virus
    Viruses2012, 4, 397-413; doi:10.3390/v4030397 OPEN ACCESS viruses ISSN 1999-4915 www.mdpi.com/journal/viruses Review Innate Immunity Evasion by Dengue Virus Juliet Morrison, Sebastian Aguirre and Ana Fernandez-Sesma * Department of Microbiology and the Global Health and Emerging Pathogens Institute (GHEPI), Mount Sinai School of Medicine, New York, NY 10029-6574, USA; E-Mails: [email protected] (J.M.); [email protected] (S.A.) * Author to whom correspondence should be addressed: E-Mail: [email protected]; Tel.: +1-212-241-5182; Fax: +1-212-534-1684. Received: 30 January 2012; in revised version: 14 February 2012 / Accepted: 7 March 2012 / Published: 15 March 2012 Abstract: For viruses to productively infect their hosts, they must evade or inhibit important elements of the innate immune system, namely the type I interferon (IFN) response, which negatively influences the subsequent development of antigen-specific adaptive immunity against those viruses. Dengue virus (DENV) can inhibit both type I IFN production and signaling in susceptible human cells, including dendritic cells (DCs). The NS2B3 protease complex of DENV functions as an antagonist of type I IFN production, and its proteolytic activity is necessary for this function. DENV also encodes proteins that antagonize type I IFN signaling, including NS2A, NS4A, NS4B and NS5 by targeting different components of this signaling pathway, such as STATs. Importantly, the ability of the NS5 protein to bind and degrade STAT2 contributes to the limited host tropism of DENV to humans and non-human primates. In this review, we will evaluate the contribution of innate immunity evasion by DENV to the pathogenesis and host tropism of this virus.
    [Show full text]
  • Guide for Common Viral Diseases of Animals in Louisiana
    Sampling and Testing Guide for Common Viral Diseases of Animals in Louisiana Please click on the species of interest: Cattle Deer and Small Ruminants The Louisiana Animal Swine Disease Diagnostic Horses Laboratory Dogs A service unit of the LSU School of Veterinary Medicine Adapted from Murphy, F.A., et al, Veterinary Virology, 3rd ed. Cats Academic Press, 1999. Compiled by Rob Poston Multi-species: Rabiesvirus DCN LADDL Guide for Common Viral Diseases v. B2 1 Cattle Please click on the principle system involvement Generalized viral diseases Respiratory viral diseases Enteric viral diseases Reproductive/neonatal viral diseases Viral infections affecting the skin Back to the Beginning DCN LADDL Guide for Common Viral Diseases v. B2 2 Deer and Small Ruminants Please click on the principle system involvement Generalized viral disease Respiratory viral disease Enteric viral diseases Reproductive/neonatal viral diseases Viral infections affecting the skin Back to the Beginning DCN LADDL Guide for Common Viral Diseases v. B2 3 Swine Please click on the principle system involvement Generalized viral diseases Respiratory viral diseases Enteric viral diseases Reproductive/neonatal viral diseases Viral infections affecting the skin Back to the Beginning DCN LADDL Guide for Common Viral Diseases v. B2 4 Horses Please click on the principle system involvement Generalized viral diseases Neurological viral diseases Respiratory viral diseases Enteric viral diseases Abortifacient/neonatal viral diseases Viral infections affecting the skin Back to the Beginning DCN LADDL Guide for Common Viral Diseases v. B2 5 Dogs Please click on the principle system involvement Generalized viral diseases Respiratory viral diseases Enteric viral diseases Reproductive/neonatal viral diseases Back to the Beginning DCN LADDL Guide for Common Viral Diseases v.
    [Show full text]
  • Characterization of the Rubella Virus Nonstructural Protease Domain and Its Cleavage Site
    JOURNAL OF VIROLOGY, July 1996, p. 4707–4713 Vol. 70, No. 7 0022-538X/96/$04.0010 Copyright q 1996, American Society for Microbiology Characterization of the Rubella Virus Nonstructural Protease Domain and Its Cleavage Site 1 2 2 1 JUN-PING CHEN, JAMES H. STRAUSS, ELLEN G. STRAUSS, AND TERYL K. FREY * Department of Biology, Georgia State University, Atlanta, Georgia 30303,1 and Division of Biology, California Institute of Technology, Pasadena, California 911252 Received 27 October 1995/Accepted 3 April 1996 The region of the rubella virus nonstructural open reading frame that contains the papain-like cysteine protease domain and its cleavage site was expressed with a Sindbis virus vector. Cys-1151 has previously been shown to be required for the activity of the protease (L. D. Marr, C.-Y. Wang, and T. K. Frey, Virology 198:586–592, 1994). Here we show that His-1272 is also necessary for protease activity, consistent with the active site of the enzyme being composed of a catalytic dyad consisting of Cys-1151 and His-1272. By means of radiochemical amino acid sequencing, the site in the polyprotein cleaved by the nonstructural protease was found to follow Gly-1300 in the sequence Gly-1299–Gly-1300–Gly-1301. Mutagenesis studies demonstrated that change of Gly-1300 to alanine or valine abrogated cleavage. In contrast, Gly-1299 and Gly-1301 could be changed to alanine with retention of cleavage, but a change to valine abrogated cleavage. Coexpression of a construct that contains a cleavage site mutation (to serve as a protease) together with a construct that contains a protease mutation (to serve as a substrate) failed to reveal trans cleavage.
    [Show full text]
  • Validation of the Easyscreen Flavivirus Dengue Alphavirus Detection Kit
    RESEARCH ARTICLE Validation of the easyscreen flavivirus dengue alphavirus detection kit based on 3base amplification technology and its application to the 2016/17 Vanuatu dengue outbreak 1 1 1 2 2 Crystal Garae , Kalkoa Kalo , George Junior Pakoa , Rohan Baker , Phill IsaacsID , 2 Douglas Spencer MillarID * a1111111111 1 Vila Central Hospital, Port Vila, Vanuatu, 2 Genetic Signatures, Sydney, Australia a1111111111 a1111111111 * [email protected] a1111111111 a1111111111 Abstract Background OPEN ACCESS The family flaviviridae and alphaviridae contain a diverse group of pathogens that cause sig- Citation: Garae C, Kalo K, Pakoa GJ, Baker R, nificant morbidity and mortality worldwide. Diagnosis of the virus responsible for disease is Isaacs P, Millar DS (2020) Validation of the easyscreen flavivirus dengue alphavirus detection essential to ensure patients receive appropriate clinical management. Very few real-time kit based on 3base amplification technology and its RT-PCR based assays are able to detect the presence of all members of these families application to the 2016/17 Vanuatu dengue using a single primer and probe set. We have developed a novel chemistry, 3base, which outbreak. PLoS ONE 15(1): e0227550. https://doi. org/10.1371/journal.pone.0227550 simplifies the viral nucleic acids allowing the design of RT-PCR assays capable of pan-fam- ily identification. Editor: Abdallah M. Samy, Faculty of Science, Ain Shams University (ASU), EGYPT Methodology/Principal finding Received: April 11, 2019 Synthetic constructs, viral nucleic acids, intact viral particles and characterised reference Accepted: December 16, 2019 materials were used to determine the specificity and sensitivity of the assays. Synthetic con- Published: January 17, 2020 structs demonstrated the sensitivities of the pan-flavivirus detection component were in the Copyright: © 2020 Garae et al.
    [Show full text]
  • Bornavirus Immunopathogenesis in Rodents: Models for Human Neurological Diseases
    Journal of NeuroVirology (1999) 5, 604 ± 612 ã 1999 Journal of NeuroVirology, Inc. http://www.jneurovirology.com Bornavirus immunopathogenesis in rodents: models for human neurological diseases Thomas Briese1, Mady Hornig1 and W Ian Lipkin*,1 1Laboratory for the Study of Emerging Diseases, Department of Neurology, 3101 Gillespie Neuroscience Research Facility, University of California, Irvine, California, CA 92697-4292, USA Although the question of human BDV infection remains to be resolved, burgeoning interest in this unique pathogen has provided tools for exploring the pharmacology and neurochemistry of neuropsychiatric disorders poten- tially linked to BDV infection. Two animal models have been established based on BDV infection of adult or neonatal Lewis rats. Analyis of these models is already yielding insights into mechanisms by which neurotropic agents and/or immune factors may impact developing or mature CNS circuitry to effect complex disturbances in movement and behavior. Keywords: Borna disease virus; neurotropism; humoral and cellular immune response; Th1 ±Th2 shift; apoptosis; dopamine; cytokines Introduction Borna disease virus (BDV), the prototype of a new disorders and schizophrenia (Amsterdam et al, family, Bornaviridae, within the nonsegmented 1985; Bode et al, 1988, 1992, 1993; Fu et al, 1993; negative-strand RNA viruses, infects the central Kishi et al, 1995; Waltrip II et al, 1995), others have nervous system (CNS) of warmblooded animals to not succeeded in replicating these ®ndings (Iwata et cause behavioral disturbances reminiscent of au- al, 1998; Kubo et al, 1997; Lieb et al, 1997; Richt et tism, schizophrenia, and mood disorders (Lipkin et al, 1997). Here we review two rodent models of al, 1995).
    [Show full text]
  • Where Do We Stand After Decades of Studying Human Cytomegalovirus?
    microorganisms Review Where do we Stand after Decades of Studying Human Cytomegalovirus? 1, 2, 1 1 Francesca Gugliesi y, Alessandra Coscia y, Gloria Griffante , Ganna Galitska , Selina Pasquero 1, Camilla Albano 1 and Matteo Biolatti 1,* 1 Laboratory of Pathogenesis of Viral Infections, Department of Public Health and Pediatric Sciences, University of Turin, 10126 Turin, Italy; [email protected] (F.G.); gloria.griff[email protected] (G.G.); [email protected] (G.G.); [email protected] (S.P.); [email protected] (C.A.) 2 Complex Structure Neonatology Unit, Department of Public Health and Pediatric Sciences, University of Turin, 10126 Turin, Italy; [email protected] * Correspondence: [email protected] These authors contributed equally to this work. y Received: 19 March 2020; Accepted: 5 May 2020; Published: 8 May 2020 Abstract: Human cytomegalovirus (HCMV), a linear double-stranded DNA betaherpesvirus belonging to the family of Herpesviridae, is characterized by widespread seroprevalence, ranging between 56% and 94%, strictly dependent on the socioeconomic background of the country being considered. Typically, HCMV causes asymptomatic infection in the immunocompetent population, while in immunocompromised individuals or when transmitted vertically from the mother to the fetus it leads to systemic disease with severe complications and high mortality rate. Following primary infection, HCMV establishes a state of latency primarily in myeloid cells, from which it can be reactivated by various inflammatory stimuli. Several studies have shown that HCMV, despite being a DNA virus, is highly prone to genetic variability that strongly influences its replication and dissemination rates as well as cellular tropism. In this scenario, the few currently available drugs for the treatment of HCMV infections are characterized by high toxicity, poor oral bioavailability, and emerging resistance.
    [Show full text]
  • WO 2010/142017 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 16 December 2010 (16.12.2010) WO 2010/142017 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 48/00 (2006.01) A61P 37/04 (2006.01) kind of national protection available): AE, AG, AL, AM, A61P 31/00 (2006.01) A61K 38/21 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) Number: International Application DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/CA20 10/000844 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 8 June 2010 (08.06.2010) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (26) Publication Language: English TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/185,261 9 June 2009 (09.06.2009) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, (71) Applicant (for all designated States except US): DE- ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, FYRUS, INC .
    [Show full text]
  • Alphavirus Vectors for Therapy of Neurological Disorders Kenneth Lundstrom* Pantherapeutics, Rue Des Remparts 4, CH1095 Lutry, Switzerland
    ell Res C ea m rc te h S & f o T h l Journal of Lundstrom, J Stem Cell Res Ther 2012, S4 e a r n a r p u DOI: 10.4172/2157-7633.S4-002 y o J ISSN: 2157-7633 Stem Cell Research & Therapy Review Article Open Access Alphavirus Vectors for Therapy of Neurological Disorders Kenneth Lundstrom* PanTherapeutics, Rue des Remparts 4, CH1095 Lutry, Switzerland Abstract Alphavirus vectors engineered for gene delivery and expression of heterologous proteins have been considered as valuable tools for research on neurological disorders. They possess a highly efficient susceptibility for neuronal cells and can provide extreme levels of heterologous gene expression. However, they generally generate short-term transient expression, which might limit their therapeutic use in many neurological disorders often requiring long-term even life-long presence of therapeutic agents. Recent development in gene silencing applying both RNA interference and microRNA approaches will certainly expand the application range. Moreover, alphaviruses provide interesting models for neurological diseases such as demyelinating and spinal motor diseases. Keywords: Alphaviruses; Gene delivery; Neuronal expression; Gene injections into the caudate nucleus showed strong neuronal expression silencing. throughout the 6 month study. No expression was observed in astrocytes and oligodendroglial cells. SV40-based delivery caused no Introduction evidence of inflammation or tissue damage. Both viral and non-viral vectors have provided interesting novel Despite these encouraging results obtained with both non-viral approaches in research on neurological disorders with a great potential and viral vectors described above alternative gene delivery methods for future therapeutic applications too [1,2].
    [Show full text]
  • Taxonomy of the Order Bunyavirales: Update 2019
    Archives of Virology (2019) 164:1949–1965 https://doi.org/10.1007/s00705-019-04253-6 VIROLOGY DIVISION NEWS Taxonomy of the order Bunyavirales: update 2019 Abulikemu Abudurexiti1 · Scott Adkins2 · Daniela Alioto3 · Sergey V. Alkhovsky4 · Tatjana Avšič‑Županc5 · Matthew J. Ballinger6 · Dennis A. Bente7 · Martin Beer8 · Éric Bergeron9 · Carol D. Blair10 · Thomas Briese11 · Michael J. Buchmeier12 · Felicity J. Burt13 · Charles H. Calisher10 · Chénchén Cháng14 · Rémi N. Charrel15 · Il Ryong Choi16 · J. Christopher S. Clegg17 · Juan Carlos de la Torre18 · Xavier de Lamballerie15 · Fēi Dèng19 · Francesco Di Serio20 · Michele Digiaro21 · Michael A. Drebot22 · Xiaˇoméi Duàn14 · Hideki Ebihara23 · Toufc Elbeaino21 · Koray Ergünay24 · Charles F. Fulhorst7 · Aura R. Garrison25 · George Fú Gāo26 · Jean‑Paul J. Gonzalez27 · Martin H. Groschup28 · Stephan Günther29 · Anne‑Lise Haenni30 · Roy A. Hall31 · Jussi Hepojoki32,33 · Roger Hewson34 · Zhìhóng Hú19 · Holly R. Hughes35 · Miranda Gilda Jonson36 · Sandra Junglen37,38 · Boris Klempa39 · Jonas Klingström40 · Chūn Kòu14 · Lies Laenen41,42 · Amy J. Lambert35 · Stanley A. Langevin43 · Dan Liu44 · Igor S. Lukashevich45 · Tāo Luò1 · Chuánwèi Lüˇ 19 · Piet Maes41 · William Marciel de Souza46 · Marco Marklewitz37,38 · Giovanni P. Martelli47 · Keita Matsuno48,49 · Nicole Mielke‑Ehret50 · Maria Minutolo3 · Ali Mirazimi51 · Abulimiti Moming14 · Hans‑Peter Mühlbach50 · Rayapati Naidu52 · Beatriz Navarro20 · Márcio Roberto Teixeira Nunes53 · Gustavo Palacios25 · Anna Papa54 · Alex Pauvolid‑Corrêa55 · Janusz T. Pawęska56,57 · Jié Qiáo19 · Sheli R. Radoshitzky25 · Renato O. Resende58 · Víctor Romanowski59 · Amadou Alpha Sall60 · Maria S. Salvato61 · Takahide Sasaya62 · Shū Shěn19 · Xiǎohóng Shí63 · Yukio Shirako64 · Peter Simmonds65 · Manuela Sironi66 · Jin‑Won Song67 · Jessica R. Spengler9 · Mark D. Stenglein68 · Zhèngyuán Sū19 · Sùróng Sūn14 · Shuāng Táng19 · Massimo Turina69 · Bó Wáng19 · Chéng Wáng1 · Huálín Wáng19 · Jūn Wáng19 · Tàiyún Wèi70 · Anna E.
    [Show full text]
  • Rousettus Aegyptiacus Amy J
    Schuh et al. Parasites & Vectors (2016) 9:128 DOI 10.1186/s13071-016-1390-z SHORT REPORT Open Access No evidence for the involvement of the argasid tick Ornithodoros faini in the enzootic maintenance of marburgvirus within Egyptian rousette bats Rousettus aegyptiacus Amy J. Schuh1, Brian R. Amman1, Dmitry A. Apanaskevich2, Tara K. Sealy1, Stuart T. Nichol1 and Jonathan S. Towner1* Abstract Background: The cave-dwelling Egyptian rousette bat (ERB; Rousettus aegyptiacus) was recently identified as a natural reservoir host of marburgviruses. However, the mechanisms of transmission for the enzootic maintenance of marburgviruses within ERBs are unclear. Previous ecological investigations of large ERB colonies inhabiting Python Cave and Kitaka Mine, Uganda revealed that argasid ticks (Ornithodoros faini) are hematophagous ectoparasites of ERBs. Yet, their potential role as transmission vectors for marburgvirus has not been sufficiently assessed. Findings: In the present study, 3,125 O. faini were collected during April 2013 from the rock crevices of Python Cave, Uganda. None of the ticks tested positive for marburgvirus-specific RNA by Q-RT-PCR. The probability of failure to detect marburgvirus at a conservative prevalence of 0.1 % was 0.05. Conclusions: The absence of marburgvirus RNA in O. faini suggests they do not play a significant role in the transmission and enzootic maintenance of marburgvirus within their natural reservoir host. Keywords: Filovirus, Marburgvirus, Marburg virus, Tick, Argasid, Ornithodoros, Egyptian rousette bat, Rousettus aegyptiacus, Transmission, Maintenance Findings IgG antibodies [3, 4] and the isolation of infectious mar- Introduction burgvirus [1–3, 5] from ERBs inhabiting caves associated The genus Marburgvirus (Filoviridae), includes a single with recent human outbreaks.
    [Show full text]
  • Interaction with Other Flaviviruses (Pre-Existing Immunity, Co-Infection, Cross- Reactivity)
    Interaction with other flaviviruses (pre-existing immunity, co-infection, cross- reactivity) Alan D.T. Barrett Department of Pathology Sealy Center for Vaccine Development University of Texas Medical Branch Galveston TX Flavivirus genome 50nm particle. SS, +RNA genome. 10 genes, 3 structural. Beck, A. Barrett, ADT. (2015) Exp Rev Vaccines. 1-14. 2 Flavivirus E protein epitopes • Studies with human and mouse polyclonal sera show extensive serologic cross-reactivities between flaviviruses in terms of physical (ELISA) and biological (HAI and neutralization) assays • Studies with mouse, non-human primate, and human monoclonal antibodies show essentially the same result that all flaviviruses studied to date have a range of E protein epitopes ranging in flavivirus cross-reactive (e.g., mab 4G2 or 6B6C-1), to flavivirus intermediate (e.g., mab 1B7), to serocomplex specific (e.g., DENV-1 to DENV-4; mab MDVP-55A), to flavivirus species specific (e.g., mab 3H5 that is DENV-2 specific). Strain specific epitopes are rare. • Flavivirus infection induces a range of antibodies, including those that recognize multiple flaviviruses. A second, but different, flavivirus infection potentiates induction of flavivirus cross-reactive antibodies. • Most epitopes are “conformational” or “quaternary”. Very few epitopes are linear. Very few epitopes appear to elicit high titer neutralizing antibodies. Reactivity of anti-E protein mouse monoclonal antibodies raised against YF 17D vaccine with YF and 37 other flaviviruses RH: Rabbit hyperimune sera Gould et al., 1985 Reactivity of anti-E protein mouse monoclonal antibodies raised against YF 17D vaccine with YF and 37 other flaviviruses RH: Rabbit hyperimune sera Gould et al., 1985 Reactivity of anti-E and anti-NS1 protein mouse monoclonal antibodies raised against YF 17D vaccine with different YF strains Flavivirus NS1 protein Less flavivirus cross-reactive epitopes than E protein, but some still identified.
    [Show full text]